NEW YORK (GenomeWeb News) — Sanofi-aventis and Scripps Genomic Medicine have formed a strategic alliance designed to advance R&D initiatives in individualized medicine.
Under terms of the alliance announced today, a Sanofi-aventis Group subsidiary, Sanofi-aventis Recherche & Developpement, will fund up to three Discovery Innovation Grants per year. The grants are intended to offer flexible financing for innovative research proposals from investigators at Scripps Genomic Medicine, a division of Scripps Health, the private not-for-profit community health system based in San Diego.
In return, Sanofi-aventis will be granted non-exclusive rights to any research tools developed through these grants, as well as preferred access to Scripps laboratory facilities for work conducted in support of sponsored research agreements and technologies, or discoveries in the field of personalized medicine.
Also, Sanofi-aventis will have access to Scripps research programs that can contribute to the company's priority areas through ongoing scientific exchange and collaboration efforts — including an annual research symposium to be jointly organized by Sanofi-aventis and Scripps, the partners said.
"The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development," Eric Topol, Scripps Health's chief academic officer, said in a statement.